Evidence map›Paper›PMID 36285702›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Toward a Deeper Understanding of Gut Microbiome in Depression: The Promise of Clinical Applicability.

Lanxiang Liu, Haiyang Wang, Hanping Zhang, Xueyi Chen, Yangdong Zhang, Ji Wu, Libo Zhao, Dongfang Wang, Juncai Pu, Ping Ji and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 4 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 4 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Effects ofFrontiers in psychiatry · 2026
    Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. TheFoods (Basel, Switzerland) · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lanxiang LiuDepartment of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Haiyang WangNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Hanping ZhangNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xueyi ChenNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yangdong ZhangNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ji WuNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Libo ZhaoDepartment of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Dongfang WangNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Juncai PuNHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ping JiCollege of Stomatology and Affiliated Stomatological Hospital of Chongqing Medical University, Chongqing, 401147, China.
Peng XieDepartment of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.ORCID 0000-0002-0081-6048
The Affiliated Yongchuan Hospital of Chongqing Medical University · CNStomatological Hospital of Chongqing Medical University · CNChongqing Medical University · CN

Funding

China Postdoctoral Science Foundation 2020M683634XBChina Postdoctoral Science Foundation 2020TQ0393China Postdoctoral Science Foundation 2021M693926Chongqing Science & Technology Commission cstc2021jcyj-bshX0150Chongqing Science & Technology Commission cstc2021jcyj-bshX0201Natural Science Foundation Project of China 81820108015Natural Science Foundation Project of China 82201683
6 · The paper itself

Abstract

The emergence of the coronavirus disease 2019 pandemic has dramatically increased the global prevalence of depression. Unfortunately, antidepressant drugs benefit only a small minority of patients. Thus, there is an urgent need to develop new interventions. Accumulating evidence supports a causal relationship between gut microbiota dysbiosis and depression. To advance microbiota-based diagnostics and therapeutics of depression, a comprehensive overview of microbial alterations in depression is presented to identify effector microbial biomarkers. This procedure generated 215 bacterial taxa from humans and 312 from animal models. Compared to controls, depression shows significant differences in β-diversity, but no changes in microbial richness and diversity. Additionally, species-specific microbial changes are identified like increased Eggerthella in humans and decreased Acetatifactor in rodent models. Moreover, a disrupted microbiome balance and functional changes, characterized by an enrichment of pro-inflammatory bacteria (e.g., Desulfovibrio and Escherichia/Shigella) and depletion of anti-inflammatory butyrate-producing bacteria (e.g., Bifidobacterium and Faecalibacterium) are consistently shared across species. Confounding effects of geographical region, depression type, and intestinal segments are also investigated. Ultimately, a total of 178 species and subspecies probiotics are identified to alleviate the depressive phenotypes. Current findings provide a foundation for developing microbiota-based diagnostics and therapeutics and advancing microbiota-oriented precision medicine for depression.

Indexed as

COVID-19Gastrointestinal MicrobiomeMicrobiotaAnimalsBacteriaDepressionHumansIntestinesdepressiongut microbiomemicrobial biomarkersmicrobiota-based therapeuticsprecision medicine

Identifiers

PMID36285702
PMCPMC9762301
OpenAlexW4307338134

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.